Portola Pharmaceuticals, Inc. Announces Release of Lock-up Restriction for Common Stock Held by a Director of the Company

Published: Oct 16, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SOUTH SAN FRANCISCO, Calif., Oct. 15, 2013 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) announced today that Morgan Stanley & Co. LLC and Credit Suisse Securities (USA) LLC, the joint book-running managers in the Company's recent public sale of 9,686,171 shares of common stock, are releasing a lock-up restriction with respect to 95,962 shares of the Company's common stock held by a director of the Company. The release will take effect concurrently with the pricing of the proposed public offering under a registration statement on Form S-1 initially filed by the Company on October 7, 2013, for the purpose of allowing the director to sell those shares in the proposed public offering.

Help employers find you! Check out all the jobs and post your resume.

Back to news